Cargando…

Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy

INTRODUCTION: The androgen receptor (AR) is the master regulator of prostate cancer cell metabolism. Degarelix is a novel gonadotrophin-releasing hormone blocker, used to decrease serum androgen levels in order to treat advanced human prostate cancer. Little is known of the rapid metabolic response...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhu, Basetti, Shaw, Greg L., Warren, Anne Y., Neal, David E., Griffiths, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927592/
https://www.ncbi.nlm.nih.gov/pubmed/27429605
http://dx.doi.org/10.1007/s11306-016-1055-0
_version_ 1782440282582679552
author Madhu, Basetti
Shaw, Greg L.
Warren, Anne Y.
Neal, David E.
Griffiths, John R.
author_facet Madhu, Basetti
Shaw, Greg L.
Warren, Anne Y.
Neal, David E.
Griffiths, John R.
author_sort Madhu, Basetti
collection PubMed
description INTRODUCTION: The androgen receptor (AR) is the master regulator of prostate cancer cell metabolism. Degarelix is a novel gonadotrophin-releasing hormone blocker, used to decrease serum androgen levels in order to treat advanced human prostate cancer. Little is known of the rapid metabolic response of the human prostate cancer tissue samples to the decreased androgen levels. OBJECTIVES: To investigate the metabolic responses in benign and cancerous tissue samples from patients after treatment with Degarelix by using HRMAS (1)H NMR spectroscopy. METHODS: Using non-destructive HR-MAS (1)H NMR spectroscopy we analysed the metabolic changes induced by decreased AR signalling in human prostate cancer tissue samples. Absolute concentrations of the metabolites alanine, lactate, glutamine, glutamate, citrate, choline compounds [t-choline = choline + phosphocholine (PC) + glycerophosphocholine (GPC)], creatine compounds [t-creatine = creatine (Cr) + phosphocreatine (PCr)], taurine, myo-inositol and polyamines were measured in benign prostate tissue samples (n = 10), in prostate cancer specimens from untreated patients (n = 7) and prostate cancer specimens from patients treated with Degarelix (n = 6). RESULTS: Lactate, alanine and t-choline concentrations were significantly elevated in high-grade prostate cancer samples when compared to benign samples in untreated patients. Decreased androgen levels resulted in significant decreases of lactate and t-choline concentrations in human prostate cancer biopsies. CONCLUSIONS: The reduced concentrations of lactate and t-choline metabolites due to Degarelix could in principle be monitored by in vivo (1)H MRS, which suggests that it would be possible to monitor the effects of physical or chemical castration in patients by that non-invasive method. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11306-016-1055-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4927592
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-49275922016-07-13 Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy Madhu, Basetti Shaw, Greg L. Warren, Anne Y. Neal, David E. Griffiths, John R. Metabolomics Original Article INTRODUCTION: The androgen receptor (AR) is the master regulator of prostate cancer cell metabolism. Degarelix is a novel gonadotrophin-releasing hormone blocker, used to decrease serum androgen levels in order to treat advanced human prostate cancer. Little is known of the rapid metabolic response of the human prostate cancer tissue samples to the decreased androgen levels. OBJECTIVES: To investigate the metabolic responses in benign and cancerous tissue samples from patients after treatment with Degarelix by using HRMAS (1)H NMR spectroscopy. METHODS: Using non-destructive HR-MAS (1)H NMR spectroscopy we analysed the metabolic changes induced by decreased AR signalling in human prostate cancer tissue samples. Absolute concentrations of the metabolites alanine, lactate, glutamine, glutamate, citrate, choline compounds [t-choline = choline + phosphocholine (PC) + glycerophosphocholine (GPC)], creatine compounds [t-creatine = creatine (Cr) + phosphocreatine (PCr)], taurine, myo-inositol and polyamines were measured in benign prostate tissue samples (n = 10), in prostate cancer specimens from untreated patients (n = 7) and prostate cancer specimens from patients treated with Degarelix (n = 6). RESULTS: Lactate, alanine and t-choline concentrations were significantly elevated in high-grade prostate cancer samples when compared to benign samples in untreated patients. Decreased androgen levels resulted in significant decreases of lactate and t-choline concentrations in human prostate cancer biopsies. CONCLUSIONS: The reduced concentrations of lactate and t-choline metabolites due to Degarelix could in principle be monitored by in vivo (1)H MRS, which suggests that it would be possible to monitor the effects of physical or chemical castration in patients by that non-invasive method. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11306-016-1055-0) contains supplementary material, which is available to authorized users. Springer US 2016-06-30 2016 /pmc/articles/PMC4927592/ /pubmed/27429605 http://dx.doi.org/10.1007/s11306-016-1055-0 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Madhu, Basetti
Shaw, Greg L.
Warren, Anne Y.
Neal, David E.
Griffiths, John R.
Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy
title Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy
title_full Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy
title_fullStr Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy
title_full_unstemmed Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy
title_short Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy
title_sort response of degarelix treatment in human prostate cancer monitored by hr-mas (1)h nmr spectroscopy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927592/
https://www.ncbi.nlm.nih.gov/pubmed/27429605
http://dx.doi.org/10.1007/s11306-016-1055-0
work_keys_str_mv AT madhubasetti responseofdegarelixtreatmentinhumanprostatecancermonitoredbyhrmas1hnmrspectroscopy
AT shawgregl responseofdegarelixtreatmentinhumanprostatecancermonitoredbyhrmas1hnmrspectroscopy
AT warrenanney responseofdegarelixtreatmentinhumanprostatecancermonitoredbyhrmas1hnmrspectroscopy
AT nealdavide responseofdegarelixtreatmentinhumanprostatecancermonitoredbyhrmas1hnmrspectroscopy
AT griffithsjohnr responseofdegarelixtreatmentinhumanprostatecancermonitoredbyhrmas1hnmrspectroscopy